0001209191-23-058708.txt : 20231214
0001209191-23-058708.hdr.sgml : 20231214
20231214201442
ACCESSION NUMBER: 0001209191-23-058708
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231212
FILED AS OF DATE: 20231214
DATE AS OF CHANGE: 20231214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bitterman Kevin
CENTRAL INDEX KEY: 0001591747
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39438
FILM NUMBER: 231488594
MAIL ADDRESS:
STREET 1: C/O POLARIS VENTURE PARTNERS
STREET 2: 1000 WINTER STREET, SUITE 3350
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Disc Medicine, Inc.
CENTRAL INDEX KEY: 0001816736
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 851613057
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 ARSENAL STREET, SUITE 101
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: (617) 674-9274
MAIL ADDRESS:
STREET 1: 321 ARSENAL STREET, SUITE 101
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: Gemini Therapeutics, Inc. /DE
DATE OF NAME CHANGE: 20210209
FORMER COMPANY:
FORMER CONFORMED NAME: FS Development Corp.
DATE OF NAME CHANGE: 20200702
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-12
0
0001816736
Disc Medicine, Inc.
IRON
0001591747
Bitterman Kevin
C/O DISC MEDICINE, INC.
321 ARSENAL STREET, SUITE 101
WATERTOWN
MA
02472
1
0
0
0
0
Common Stock
2023-12-12
4
S
0
20823
59.87
D
861401
I
See footnote
Common Stock
2023-12-12
4
S
0
422
60.99
D
860979
I
See footnote
Common Stock
2023-12-12
4
S
0
4155
62.42
D
856824
I
See footnote
Common Stock
2023-12-12
4
S
0
665
62.90
D
856159
I
See footnote
Common Stock
2023-12-12
4
S
0
688
63.78
D
855471
I
See footnote
Common Stock
2023-12-12
4
S
0
18615
65.10
D
836856
I
See footnote
Common Stock
2023-12-12
4
S
0
6599
65.77
D
830257
I
See footnote
Common Stock
2023-12-13
4
S
0
3508
59.99
D
826749
I
See footnote
Common Stock
2023-12-13
4
S
0
40
60.50
D
826709
I
See footnote
Common Stock
2023-12-14
4
S
0
20429
58.27
D
806280
I
See footnote
Common Stock
2023-12-14
4
S
0
120
59.74
D
806160
I
See footnote
Common Stock
218326
I
See footnote
Common Stock
51000
I
See footnote
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.50 to $60.497 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4), (5), (6), (7), (8), (9), (10) and (11).
These shares are held by Atlas Venture Opportunity I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.51 to $61.50 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.5297 to $62.5175 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.6436 to $63.3256 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.70 to $64.67 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.7499 to $65.735 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.745 to $66.32 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.50 to $60.4381 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.25 to $58.65 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.53 to $60.17 inclusive.
These shares are held by Atlas Venture Opportunity II, LP ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, LP ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any.
These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any.
/s/ Ommer Chohan, Attorney-in-Fact
2023-12-14